Seqens Seqens

X

Find Drugs in Development News & Deals for Veverimer

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

TRC101 (veverimer), a non-absorbed, orally administered polymer has ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD).


Lead Product(s): Veverimer

Therapeutic Area: Nephrology Product Name: TRC101

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 24, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TRC101 (veverimer), is novel, non-absorbed polymer that is designed to treat metabolic acidosis by binding hydrochloric acid in GIT and removing it from body through excretion in feces, thereby decreasing total amount of acid in body and increasing serum bicarbonate.


Lead Product(s): Veverimer

Therapeutic Area: Nephrology Product Name: TRC101

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 03, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TRC101 (veverimer), a novel, non-absorbed polymer that is designed to treat metabolic acidosis by binding hydrochloric acid in the gastrointestinal tract is specifically designed to combine high capacity and high selectivity for binding and removing hydrochloric acid.


Lead Product(s): Veverimer

Therapeutic Area: Nephrology Product Name: TRC101

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Veverimer, also known as TRC101, is a novel, non-absorbed polymer that is designed to treat metabolic acidosis by binding hydrochloric acid in the gastrointestinal tract and removing it from the body through excretion in the feces.


Lead Product(s): Veverimer

Therapeutic Area: Nephrology Product Name: TRC101

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Tricida investigational drug candidate, Veverimer, an orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD, is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression.


Lead Product(s): Veverimer

Therapeutic Area: Nephrology Product Name: TRC101

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The net proceeds will be used to fund corporate operations, including the VALOR-CKD renal outcomes trial evaluating Veverimer, and are expected to extend Tricida’s financial runway into the first quarter of 2023.


Lead Product(s): Veverimer

Therapeutic Area: Nephrology Product Name: TRC101

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Deep Track Capital

Deal Size: $42.0 million Upfront Cash: Undisclosed

Deal Type: Financing November 15, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The patent expands the composition of matter claims for veverimer to 2038 and extends the Tricida patent portfolio to a total of 210 patents in 49 different countries. Veverimer is a non-absorbed, orally-administered polymer for metabolic acidosis in patients with CKD.


Lead Product(s): Veverimer

Therapeutic Area: Nephrology Product Name: TRC101

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Tricida Has Received an Appeal Denied Letter from the Office of New Drugs of the FDA in Response to its Formal Dispute Resolution Request. The ongoing VALOR-CKD trial is a renal outcomes clinical trial designed to determine if veverimer slows CKD progression.


Lead Product(s): Veverimer

Therapeutic Area: Nephrology Product Name: TRC101

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 25, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Tricida has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for veverimer on August 21, 2020. The NDA was reviewed under the Accelerated Approval Program.


Lead Product(s): Veverimer

Therapeutic Area: Nephrology Product Name: TRC101

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY